Vanguard Personalized Indexing Management LLC Increases Position in Astrazeneca Plc $AZN

Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 6.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 142,455 shares of the company’s stock after acquiring an additional 8,147 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Astrazeneca were worth $25,001,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Triumph Capital Management acquired a new stake in Astrazeneca during the third quarter valued at approximately $25,000. Bangor Savings Bank raised its stake in Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares in the last quarter. Eagle Bay Advisors LLC acquired a new stake in Astrazeneca during the fourth quarter valued at approximately $30,000. YANKCOM Partnership acquired a new stake in Astrazeneca during the fourth quarter valued at approximately $31,000. Finally, TFC Financial Management Inc. raised its stake in Astrazeneca by 3,350.0% during the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock valued at $32,000 after buying an additional 335 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AZN has been the topic of several research reports. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Barclays restated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Finally, UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Up 0.0%

NYSE:AZN opened at $178.79 on Monday. The firm has a market capitalization of $277.28 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 1.55 and a beta of 0.25. The stock has a 50 day moving average of $189.26 and a 200-day moving average of $186.07. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Analysts predict that Astrazeneca Plc will post 9.39 EPS for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.